Business
3 things to expect from Novavax in 2021
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Novavax Inc (NASDAQ: NVAX) shares gained more than 2,600% last year as the clinical-stage biotech became one of the front-runners in the race to develop a coronavirus vaccine — and was awarded $1.6 billion from the United States Government to support its efforts.
That was a genuinely amazing performance, and as 2021 begins, Novavax still has a lot on its agenda. Here are three things investors should be looking for from the company this year.
1. A possible coronavirus vaccine — and revenue
Novavax has a late-stage clinical trial for its coronavirus vaccine candidate, NVX-CoV2373, well underway in the United Kingdom, and…
-
Noosa News19 hours agoJessica Alba spotted filming spy thriller on the Gold Coast as cameras roll under iconic bridge
-
Noosa News15 hours agoNoosa Council targeted in fraud
-
Noosa News16 hours agoDavid’s neighbour died alone. He now knows what comes next
-
General18 hours agoACT family violence victims ‘waiting 3 or 4 days’ for help, inquiry hears